Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Vincent

Physician Assistant, Medical Bloomfield, CT Physician Assistant

NPI 1487985065 CMS profile 10774615

711 Cottage Grove Rd, Bloomfield, CT 06002

Open in the dashboard

General payments

$6,233

298 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Vincent of Bloomfield, CT is reported in the CMS Open Payments database as having received $6,233 across 298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,483 56
2024 General $1,572 64
2023 General $687 34
2022 General $1,033 42
2021 General $1,458 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Vincent
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Erin Vincent were reported at $1,483. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Erin Vincent Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,458 $156 $41–$563 $132
2022 $1,033 $185 $55–$649 $149
2023 $687 $199 $58–$717 $160
2024 $1,572 $206 $62–$740 $164
2025 $1,483 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,260 68 payments
  2. AstraZeneca Pharmaceuticals LP $504 24 payments
  3. Novartis Pharmaceuticals Corporation $497 18 payments
  4. Amgen Inc. $366 17 payments
  5. E.R. Squibb & Sons, L.L.C. $364 27 payments
  6. Janssen Pharmaceuticals, Inc $339 24 payments
  7. Boston Scientific Corporation $323 9 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $319 14 payments
  9. Esperion Therapeutics, Inc. $262 11 payments
  10. Amarin Pharma Inc. $207 13 payments
  11. Other $1,792 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,077 296 payments
  2. Consulting Fee $156 2 payments
Products named General payments · program years 2021–2025
  1. LEQVIO $433 15 payments
  2. JOT DX $378 13 payments
  3. XARELTO $339 24 payments
  4. CAMZYOS $277 20 payments
  5. Repatha $275 13 payments
  6. NEXLETOL $262 11 payments
  7. Confirm Rx $247 16 payments
  8. FARXIGA $240 14 payments
  9. Vascepa $207 13 payments
  10. JARDIANCE $203 8 payments
  11. Other $3,492 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

754

Median for Physician Assistant: 241

Drug cost

$150,549

Median for Physician Assistant: $4,110

Branded share of claims

26.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 84 $84,386
Xarelto Rivaroxaban Brand 17 $21,676
Entresto Sacubitril/Valsartan Brand 13 $14,792
Brilinta Ticagrelor Brand 11 $12,942
Jardiance Empagliflozin Brand 14 $9,543
Metoprolol Succinate Generic 121 $1,384
Ezetimibe Generic 54 $1,107
Atorvastatin Calcium Generic 95 $1,084
Rosuvastatin Calcium Generic 44 $895
Lisinopril Generic 37 $569

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$7,066

Medicare's payments for the services billed

Medicare patients

91

Average age 79

Services billed

162

39 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 65%
Atrial fibrillation 52%
Diabetes 46%
Chronic kidney disease 46%
Arthritis 36%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $199
$199 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $169
$169 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $156
$156 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $96
$96 14 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record